🇺🇸 FDA

Company profile · Sponsor

Seres

Seres Therapeutics

MCRB · NYSE pharma CAMBRIDGE, MA, USA
Pipeline
8
Drugs
0
Patents
8

Quick answer

Seres (MCRB) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker MCRB
Exchange NYSE
Company type pharma
Headquarters CAMBRIDGE, MA, USA
SEC CIK 0001609809

Pipeline (8)

Search pipeline →

  1. SER-109

    Seres

    Clostridioides Difficile Infection

    phase 3 mab completed

    1 trial

  2. SER-109

    Seres

    Clostridium Difficile Infection

    phase 3 mab completed

    1 trial

  3. SER-109

    Seres

    Clostridium Difficile

    phase 2 small molecule completed

    1 trial

  4. Vancomycin Pre-Treatment

    Seres

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  5. Placebo for antibiotic

    Seres

    Metastatic Melanoma

    phase 1 small molecule completed

    1 trial

  6. SER-262

    Seres

    Clostridium Difficile Infection

    phase 1 small molecule completed

    1 trial

  7. SER-287

    Seres

    Ulcerative Colitis

    phase 1 small molecule completed

    1 trial

  8. Vancomycin Pre-Treatment

    Seres

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12409197

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12214002

    Compositions and methods for treating antibiotic resistance

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11918612

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11730775

    Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11701394

    Compositions and methods for treating cholestatic disease

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11666612

    Network-based microbial compositions and methods

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11464812

    Synergistic bacterial compositions and methods of production and use thereof

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Seres?

Seres (MCRB) is a pharma company. headquartered in CAMBRIDGE, MA, USA. listed on NYSE. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Seres sponsor?

We track 8 ClinicalTrials.gov-linked programs for Seres, including SER-109 and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Seres company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.